Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Get Free Report) have been given an average recommendation of "Moderate Buy" by the seven research firms that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, five have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $29.00.
KYTX has been the topic of several recent analyst reports. Wall Street Zen lowered Kyverna Therapeutics from a "sell" rating to a "strong sell" rating in a report on Saturday. Benchmark reissued a "buy" rating on shares of Kyverna Therapeutics in a report on Friday, September 25th. Needham & Company LLC set a $25.00 target price on Kyverna Therapeutics in a research report on Friday, September 25th. HC Wainwright reissued a "buy" rating on shares of Kyverna Therapeutics in a research note on Thursday, October 22nd. Finally, William Blair upgraded Kyverna Therapeutics to a "strong-buy" rating in a research note on Wednesday, September 23rd.
Read Our Latest Stock Report on KYTX
Kyverna Therapeutics Trading Down 2.5%
Shares of NASDAQ KYTX opened at $4.26 on Friday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 7.01 and a current ratio of 7.01. The business's 50 day moving average price is $5.90 and its 200-day moving average price is $7.79. Kyverna Therapeutics has a fifty-two week low of $4.18 and a fifty-two week high of $13.67. The company has a market cap of $269.33 million, a price-to-earnings ratio of -1.54 and a beta of 2.12.
Kyverna Therapeutics (NASDAQ:KYTX - Get Free Report) last issued its earnings results on Thursday, November 12th. The company reported ($0.68) EPS for the quarter, topping analysts' consensus estimates of ($0.69) by $0.01. On average, sell-side analysts expect that Kyverna Therapeutics will post -2.71 earnings per share for the current year.
Institutional Investors Weigh In On Kyverna Therapeutics
Several large investors have recently made changes to their positions in the company. AIGH Capital Management LLC boosted its position in shares of Kyverna Therapeutics by 30.6% in the 3rd quarter. AIGH Capital Management LLC now owns 3,650,000 shares of the company's stock worth $24,820,000 after purchasing an additional 854,203 shares in the last quarter. BlackRock Inc. acquired a new stake in Kyverna Therapeutics during the 2nd quarter valued at $27,931,000. Goldman Sachs Group Inc. increased its position in Kyverna Therapeutics by 64.6% during the 3rd quarter. Goldman Sachs Group Inc. now owns 551,899 shares of the company's stock worth $3,753,000 after purchasing an additional 216,669 shares in the last quarter. Renaissance Technologies LLC lifted its stake in shares of Kyverna Therapeutics by 106.6% during the first quarter. Renaissance Technologies LLC now owns 367,492 shares of the company's stock valued at $3,171,000 after buying an additional 189,593 shares during the period. Finally, Bank of America Corp DE acquired a new stake in Kyverna Therapeutics during the second quarter worth about $2,365,000. 18.08% of the stock is owned by institutional investors.
About Kyverna Therapeutics
(
Get Free Report)
Kyverna Therapeutics is a clinical-stage biopharmaceutical company developing cell therapies for people with autoimmune diseases. The company's approach aims to use engineered immune cells to address disease-causing B cells. Its lead candidate, KYV-101, is an autologous CAR T-cell therapy designed to target CD19, a protein found on B cells. Kyverna is evaluating the therapy in clinical studies for several autoimmune conditions, including stiff person syndrome, myasthenia gravis and lupus nephritis.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Kyverna Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kyverna Therapeutics wasn't on the list.
While Kyverna Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.